Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
In certain embodiments an optimized derivative of the CCLc-βAS3-FB lentiviral vector termed (CCLc-mGata/ANK-CoreLCR-βAS3-FB), is provided which is capable of driving lineage-restricted expression of a beta-globin gene (e.g., an anti-sickling β-globin like gene (βA83)). In certain embodiments the vectors described herein comprise novel defined LCR HS core sequences (HS2(˜420 bp), HS3β40 bp), HS4(˜410 bp)) which can be used to replace the putative LCR HS sequences present within the “mini-LCR” (˜3.6 kb reduced to ˜1.2 kb) to produce an “optimized mini-LCR”.
1. A recombinant lentiviral vector (LV) comprising:
an expression cassette comprising a nucleic acid construct comprising:
a human β-globin locus control region consisting of a hypersensitive site (HS) core sequence consisting of:
an HS2 core sequence that consists of a nucleic acid sequence ranging from nucleotide 5484 to 5908 of SEO ID NO: 1;
an HS3 core sequence that consists of a nucleic acid sequence ranging from nucleotide 5909 to 6252 of SEO ID NO: 1; and
an HS4 core sequence that consists of a nucleic acid sequence ranging from nucleotide 6253 to 6662 of SEO ID NO: 1;
and a recombinant human beta globin gene encoding a beta globin polypeptide, wherein said LV is a TAT-independent and self-inactivating (SIN) lentiviral vector.
2. The vector of claim 1 , wherein said human beta globin gene comprises an anti-sickling human beta globin gene encoding an anti-sickling beta globin polypeptide.
3. The vector of claim 2 , wherein said human beta globin gene comprises an anti-sickling human beta globin gene encoding an anti-sickling-beta globin polypeptide comprise one or more mutations selected from the group consisting of Gly16Asp, Glu22Ala and Thr87Gln.
4. The vector of claim 3 , wherein said vector comprises:
an anti-sickling human β-globin gene comprising about 2.3 kb of recombinant human β-globin gene including exons and introns under the control of the human β-globin gene 5′ promoter and the human β-globin 3′ enhancer; and/or
a β-globin intron 2 with a 375 bp RsaI deletion from IVS2; and/or
a β-globin gene comprising an SspI (S) to RsaI (R) deletion (˜220 bp).
5. The vector of claim 1 , wherein said vector comprises a human Ankyrin insulator element.
6. The vector of claim 5 , wherein said human ankyrin insulator is adjacent to HS4 or adjacent to HS2.
7. The vector of claim 1 , wherein said vector comprises a murine GATA1-HS2.
8. The vector of claim 7 , wherein said GATA1-HS2 is adjacent to HS2 or adjacent to HS4.
9. The vector of claim 1 , wherein said vector comprises an insulator in the 3′ LTR.
10. The vector of claim 1 , wherein said vector comprises:
a Rev Responsive Element (RRE); and/or
a ψ region vector genome packaging signal; and/or
a CMV enhancer/promoter; and/or
a Rev Responsive Element (RRE); and/or
a central polypurine tract; and/or
a post-translational regulatory element.
11. The vector of claim 1 , wherein said vector comprises the nucleic acid sequence of SEQ ID NO: 1.
12. A host cell transduced with a vector of claim 1 .